Bioconjugate Drug Development

CellMosaic offers a complete drug discovery and development program for drug conjugates and drug modifications using classical linkers and polymers. Over the years, CellMosaic has delivered many high-quality conjugate drugs for customers based on our advanced conjugation processes. These processes can be modified for new conjugate drug development for our customers.

 The services we provide include:

  • Custom design and development of conjugation strategies to fit your needs (customer owns the rights for the compound)
  • Proof-of-concept Studies: CellMosaic has in-house conjugation processes ready to quickly synthesize any drug conjugates for initial proof-of-concept studies.
  • Conjugate Drug Discovery:
    • Evaluation of the labeling sites
    • Evaluation of the linkage or labeling chemistry (stable vs. cleavable)
    • Evaluation of the linkers or polymers
  • Conjugate Drug Development:
    • Stability studies
    • Development of purification method for drug bioconjugates
    • Development of bio-analytical methods (HIC, SEC, cation or anion exchange HPLC, MS)
    • pK studies of conjugate drugs in blood and tissue extracts
    • Lipid formulation studies
    • Process development
    • Process transfer

Examples of Classical Drug Conjugates and Drug Modifications frequently done at CellMosaic:

Depending on the needs of a customer’s project, the typical turn-around time for synthesizing any drug conjugates for initial proof-of-concept is 6-8 weeks. Please contact us to discuss your project.

AqueaTether™ Therapeutics, a separate division of CellMosaic, has developed novel super-hydrophilic and high-loading AqueaTether™ linkers and polymers for drug conjugation. To explore this opportunity and learn more about AqueaTether™ platform technologies, please visit our website at

  • Oligo Based Drug Conjugate Example 1: Delivery of antisense oligonucleotides using poly lysine peptide (oligo-peptide conjugate)

    Oligo Based Drug Conjugate

    CellMosaic offers bioconjugation research and development services for biopharmaceutical companies devoted to antisense and siRNA-based therapeutics. Some of the obstacles to developing oligonucleotide analogs and siRNA-based therapeutics include limited...

  • Other Drug Conjugates Example 1: Preparation of Protein-mAb(AF647)4.5 and Peptide-mAb(AF647)4.5 conjugates.

    Other Drug Conjugates

    At CellMosaic, we go the extra miles to take care of customers' projects. There are many exploratory, challenging, and unconventional drug conjugation projects we have done for our customers. For example: Complex drug conjugates involving three or more...

  • Peptide-Drug Conjugate Example 1: Single label by design: a peptide-antibiotic conjugate

    Peptide-Drug Conjugate

    CellMosaic has a lot of experience and expertise in preparing peptide or peptidomimetic-based drug conjugates. We help our customers develop peptide labeling/conjugation strategies, synthesize the modified peptide, perform the drug conjugation, and...

  • Polymer-Drug Conjugate Example 1: Loading hydrophobic drugs onto a hydrophilic polymer

    Polymer-Drug Conjugate

    It takes years of hard work and luck to obtain a highly selective small molecule drug. Alternatively, a delivery system properly tailored to carrying potent antitumor drugs can be used. In the mid-1970s, Ringsdorf proposed covalently attaching...

  • Protein-Drug Conjugate Example 1: Synthesis of a protein-drug conjugate

    Protein-Drug Conjugate

    CellMosaic offers research and development services for bio-pharmaceutical companies that develop recombinant proteins as therapeutics. New target-specific protein drugs can be developed by conjugating drugs or toxins to recombinant proteins. We can also...